GSK
All
Newsflash
Article
-
British pharmaceutical giant GSK licenses cancer drug from China's Chimagen Biosciences in deal worth up to $750 million
GSK announced plans on Tuesday to acquire full global rights to a T-cell engager (TCE) from Chengdu-based Chimagen, targeting treatment for multiple myeloma, a type of blood cancer.
-
British pharmaceutical giant GSK licenses cancer drug from China's Chimagen Biosciences in deal worth up to $750 million
GSK announced plans on Tuesday to acquire full global rights to a T-cell engager (TCE) from Chengdu-based Chimagen, targeting treatment for multiple myeloma, a type of blood cancer.
- No data
GSK
Svmuu provides news and information related to GSK, as well as real-time data on GSK. We provide in-depth analysis and interpretation of the latest GSK developments, helping investors stay informed about GSK policy updates. Svmuu is your essential tool for keeping up with the latest GSK trends! Here, we’ll join you in keeping a close eye on GSK news and use a clear macro perspective to make sense of the uncertain future of crypto.
24H Trending
-
1
Bitcoin vs. Ethereum: A Guide to the Strengths and Choices Between the Two Crypto Giants
-
2
BNB and Investment Banking Integration: Binance's Strategic Expansion into Traditional Financial Services
-
3
Cardano (ADA): Positioning and Outlook in the Future Financial System
-
4
What is MSQ Coin? MSquare Global Token Analysis and Trading Channels
-
5
BitShares (BTS) Coin: Exchange Platforms, Founder, and Core Mechanism Analysis
-
6
In-depth Analysis of ImmutableX (IMX) Social Media Influence
-
7
MDA Coin: Moeda Loyalty Points Project Analysis and Market Status
-
8
Analysis of Top 10 Cryptocurrencies by Market Cap on OKX Platform (as of October 30, 2025)
-
9
What is POPO Coin? Analyzing Multiple Meme Token Projects with the Same Name
-
10
Bitcoin Permanently Lost: The Truth Behind the $10 Billion Rumor and Actual Quantity Estimates
Markets Today
Recommended Reading










